Effects of sublethal exposure to an antiseptic mouthrinse on representative plaque bacteria.
Although the mechanism responsible for the clinical antiplaque efficacy of oral antiseptics is generally considered to be primarily one of bactericidal activity, it has been suggested that oral antiseptics may have additional effects on bacteria exposed to sublethal levels. Studies reported herein, investigated the effects of sublethal levels of an essential oil-containing antiseptic mouthrinse (Listerine Antiseptic, Warner-Lambert Co., Morris Plains, NJ) on selected activities of representative plaque microorganisms using in vitro models. These studies demonstrated that sublethal exposure to the tested oral antiseptic can have significant effects in reducing intergeneric coaggregation, increasing bacterial generation time, and extracting endotoxin from Gram-negative bacteria. These in vitro activities can be correlated with features of plaque formation and pathogenicity seen in vivo; however, additional studies will be necessary to confirm that these mechanisms are, in fact, operative clinically.
Fine
D H
DH
Division of Oral Biology, University of Medicine and Dentistry of New Jersey, New Jersey Dental School, Newark 07103, USA.
Furgang
D
D
Lieb
R
R
Korik
I
I
Vincent
J W
JW
Barnett
M L
ML
D016976:Aggregatibacter actinomycetemcomitans / Q000187:drug effects / Q000254:growth & development / Q000472:pathogenicity; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects* / Q000472:pathogenicity; D001422:Bacterial Adhesion / Q000187:drug effects; D001433:Bacteriolysis / Q000187:drug effects; D002176:Candida albicans / Q000187:drug effects / Q000254:growth & development / Q000472:pathogenicity; D002206:Capnocytophaga / Q000187:drug effects / Q000254:growth & development / Q000472:pathogenicity; D002455:Cell Division / Q000187:drug effects; D003773:Dental Plaque / Q000382:microbiology*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004731:Endotoxins / Q000037:antagonists & inhibitors; D016967:Fusobacterium nucleatum / Q000187:drug effects / Q000254:growth & development / Q000472:pathogenicity; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000254:growth & development / Q000472:pathogenicity; D006801:Humans; D009067:Mouthwashes / Q000008:administration & dosage / Q000494:pharmacology*; D009822:Oils, Volatile / Q000008:administration & dosage / Q000494:pharmacology; D012459:Salicylates / Q000008:administration & dosage / Q000494:pharmacology; D013295:Streptococcus mutans / Q000187:drug effects / Q000254:growth & development / Q000472:pathogenicity; D013298:Streptococcus sanguis / Q000187:drug effects / Q000254:growth & development / Q000472:pathogenicity; D013729:Terpenes / Q000008:administration & dosage / Q000494:pharmacology; D014678:Veillonella / Q000187:drug effects / Q000254:growth & development / Q000472:pathogenicity
D000891:Anti-Infective Agents, Local; D004338:Drug Combinations; D004731:Endotoxins; D009067:Mouthwashes; D009822:Oils, Volatile; D012459:Salicylates; D013729:Terpenes; C057473:Listerine